177 related articles for article (PubMed ID: 35905552)
1. Efficacy of empiric macrolides versus fluoroquinolones in community-acquired pneumonia associated with atypical bacteria: A meta-analysis.
Basilim A; Wali H; Rabaan AA; Eljaaly K
Respir Med Res; 2022 Nov; 82():100931. PubMed ID: 35905552
[TBL] [Abstract][Full Text] [Related]
2. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
3. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.
Raz-Pasteur A; Shasha D; Paul M
Int J Antimicrob Agents; 2015 Sep; 46(3):242-8. PubMed ID: 26092096
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.
McCurdy S; Nenninger A; Sheets A; Keedy K; Lawrence L; Quintas M; Cammarata S
Int J Infect Dis; 2020 Aug; 97():374-379. PubMed ID: 32534142
[TBL] [Abstract][Full Text] [Related]
5. The atypical pneumonias: clinical diagnosis and importance.
Cunha BA
Clin Microbiol Infect; 2006 May; 12 Suppl 3():12-24. PubMed ID: 16669925
[TBL] [Abstract][Full Text] [Related]
6. Importance of atypical pathogens of community-acquired pneumonia.
Plouffe JF
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S35-9. PubMed ID: 10984326
[TBL] [Abstract][Full Text] [Related]
7. [The role of atypical pathogen: Mycoplasma pneumoniae and Chlamydia pneumoniae in the acute respiratory infection in childhood].
Ouchi K
Jpn J Antibiot; 2000 Jun; 53 Suppl B():13-21. PubMed ID: 12572086
[TBL] [Abstract][Full Text] [Related]
8. 13--Antibiotic therapy of community-acquired pneumonia (CAP) caused by atypical agents.
Roig J; Casal J; Gispert P; Gea E
Med Mal Infect; 2006; 36(11-12):680-9. PubMed ID: 17095177
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.
Vardakas KZ; Trigkidis KK; Falagas ME
Clin Microbiol Infect; 2017 Apr; 23(4):234-241. PubMed ID: 27965070
[TBL] [Abstract][Full Text] [Related]
10. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
[TBL] [Abstract][Full Text] [Related]
11. Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial.
Postma DF; Spitoni C; van Werkhoven CH; van Elden LJR; Oosterheert JJ; Bonten MJM
BMC Infect Dis; 2019 Jan; 19(1):17. PubMed ID: 30612559
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of atypical pathogens in community-acquired pneumonia.
Gleason PP
Pharmacotherapy; 2002 Jan; 22(1 Pt 2):2S-11S; discussion 30S-32S. PubMed ID: 11791627
[TBL] [Abstract][Full Text] [Related]
13. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.
Eliakim-Raz N; Robenshtok E; Shefet D; Gafter-Gvili A; Vidal L; Paul M; Leibovici L
Cochrane Database Syst Rev; 2012 Sep; 2012(9):CD004418. PubMed ID: 22972070
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Empiric Antibiotic Coverage in Community-Acquired Pneumonia Associated with Each Atypical Bacteria: A Meta-Analysis.
Eljaaly K; Aljabri A; Rabaan AA; Aljuhani O; Thabit AK; Alshibani M; Almangour TA
J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640338
[TBL] [Abstract][Full Text] [Related]
16. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline vs. macrolides in combination therapy for treatment of community-acquired pneumonia.
Teh B; Grayson ML; Johnson PD; Charles PG
Clin Microbiol Infect; 2012 Apr; 18(4):E71-3. PubMed ID: 22284533
[TBL] [Abstract][Full Text] [Related]
18. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
[TBL] [Abstract][Full Text] [Related]
19. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
[TBL] [Abstract][Full Text] [Related]
20. Implications for macrolide treatment in community-acquired pneumonia. Hopkins CAP Team.
Mundy LM; Oldach D; Auwaerter PG; Gaydos CA; Moore RD; Bartlett JG; Quinn TC
Chest; 1998 May; 113(5):1201-6. PubMed ID: 9596295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
